# Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

> **NCT02585843** · PHASE2,PHASE3 · COMPLETED · sponsor: **Columbia University** · enrollment: 20 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Spironolactone 100mg
- **DRUG:** Spironolactone 25mg

## Key facts

- **NCT ID:** NCT02585843
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585843, "Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02585843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*